SOPHiA GENETICS SA reported unaudited financial results for the six months ended June 30, 2026. Revenue increased 25% to $45.0 million from $36.1 million in the prior year period, driven by a 19% rise in platform analysis volume and foreign exchange benefits. The company incurred a net loss of $41.7 million compared to $39.8 million previously, with operating expenses rising due to restructuring costs and legal fees related to ongoing patent litigation against Guardant Health. Cash and cash equivalents stood at $107.7 million as of June 30, 2026. The company operates in the healthcare technology industry, providing a cloud-native software platform for analyzing complex multimodal clinical data to support precision medicine.

SOPHiA GENETICS SA entered into an underwriting agreement with TD Securities (USA) LLC on June 16, 2026, for the offering and sale of 12,104,900 ordinary shares at $4.75 per share. The offering, which closed on June 18, 2026, generated approximately $57.5 million in gross proceeds. SOPHiA GENETICS SA is a healthcare technology company providing data-driven healthcare solutions through its software platform.